Adverse events associated with albendazole and other products used for treatment of giardiasis in dogs.
Meyer
E K
EK
US Pharmacopeia, Rockville, MD 20852, USA.
D016907:Adverse Drug Reaction Reporting Systems; D015766:Albendazole / Q000009:adverse effects* / Q000627:therapeutic use; D000818:Animals; D000871:Anthelmintics / Q000009:adverse effects* / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002371:Cat Diseases / Q000139:chemically induced / Q000188:drug therapy; D002415:Cats; D004283:Dog Diseases / Q000139:chemically induced / Q000188:drug therapy*; D004285:Dogs; D005273:Fenbendazole / Q000009:adverse effects / Q000627:therapeutic use; D005873:Giardiasis / Q000188:drug therapy / Q000662:veterinary*; D008795:Metronidazole / Q000009:adverse effects / Q000627:therapeutic use; D010602:Pharmacopoeias as Topic; D011796:Quinacrine / Q000009:adverse effects / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D000871:Anthelmintics; D000981:Antiprotozoal Agents; D008795:Metronidazole; D005273:Fenbendazole; D015766:Albendazole; D011796:Quinacrine